BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34447241)

  • 1. Combination Therapy of Metastatic Castration-Recurrent Prostate Cancer: Hyaluronic Acid Decorated, Cabazitaxel-Prodrug and Orlistat Co-Loaded Nano-System.
    Qu Z; Ren Y; Shen H; Wang H; Shi L; Tong D
    Drug Des Devel Ther; 2021; 15():3605-3616. PubMed ID: 34447241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti prostate cancer therapy: Aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles.
    Chen Y; Deng Y; Zhu C; Xiang C
    Biomed Pharmacother; 2020 Jul; 127():110181. PubMed ID: 32416561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pursuing for the better lung cancer therapy effect: Comparison of two different kinds of hyaluronic acid and nitroimidazole co-decorated nanomedicines.
    Chen G; Zhang Y; Deng H; Tang Z; Mao J; Wang L
    Biomed Pharmacother; 2020 May; 125():109988. PubMed ID: 32059173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
    Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
    Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer.
    Wang Z; Zang A; Wei Y; An L; Hong D; Shi Y; Zhang J; Su S; Fang G
    Drug Des Devel Ther; 2020; 14():1095-1105. PubMed ID: 32210538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles.
    Liu J; Cheng H; Han L; Qiang Z; Zhang X; Gao W; Zhao K; Song Y
    Drug Des Devel Ther; 2018; 12():3199-3209. PubMed ID: 30288024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer.
    Zhang R; Ru Y; Gao Y; Li J; Mao S
    Drug Des Devel Ther; 2017; 11():2631-2642. PubMed ID: 28919713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer.
    Hoang B; Ernsting MJ; Tang WS; Bteich J; Undzys E; Kiyota T; Li SD
    Cancer Lett; 2017 Dec; 410():169-179. PubMed ID: 28965854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
    Yan J; Wang Y; Zhang X; Liu S; Tian C; Wang H
    Drug Deliv; 2016 Jun; 23(5):1757-62. PubMed ID: 26203689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
    Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
    Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy.
    Qu CY; Zhou M; Chen YW; Chen MM; Shen F; Xu LM
    Int J Nanomedicine; 2015; 10():3911-20. PubMed ID: 26089667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastric cancer combination therapy: synthesis of a hyaluronic acid and cisplatin containing lipid prodrug coloaded with sorafenib in a nanoparticulate system to exhibit enhanced anticancer efficacy and reduced toxicity.
    Yang F; Li A; Liu H; Zhang H
    Drug Des Devel Ther; 2018; 12():3321-3333. PubMed ID: 30323564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles.
    Wu R; Zhang Z; Wang B; Chen G; Zhang Y; Deng H; Tang Z; Mao J; Wang L
    Drug Des Devel Ther; 2020; 14():2249-2261. PubMed ID: 32606595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.
    Wang W; Xi M; Duan X; Wang Y; Kong F
    Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti prostate cancer using PEGylated bombesin containing, cabazitaxel loading nano-sized drug delivery system.
    Chen W; Guo M; Wang S
    Drug Dev Ind Pharm; 2016 Dec; 42(12):1968-1976. PubMed ID: 27143168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy.
    Gao Z; Li Z; Yan J; Wang P
    Drug Des Devel Ther; 2017; 11():2595-2604. PubMed ID: 28919710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Begemann D; Wang Y; Yang W; Kyprianou N
    Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer.
    Wan Z; Xie F; Wang L; Zhang G; Zhang H
    Int J Nanomedicine; 2020; 15():5333-5344. PubMed ID: 32801692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer.
    Qu N; Lee RJ; Sun Y; Cai G; Wang J; Wang M; Lu J; Meng Q; Teng L; Wang D; Teng L
    Int J Nanomedicine; 2016; 11():3451-9. PubMed ID: 27555767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
    Pang J; Xing H; Sun Y; Feng S; Wang S
    Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.